SCHEMBL4767052

SCHEMBL4767052

O=c1[nH]c(-c2ccnc(OCc3ccccc3)c2)cc2ccccc12

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.48
KDM4E B2RXH2 1/20 0.48
NPC1 O15118 1/20 0.48
LMNA P02545 1/20 0.48
HPGD P15428 1/20 0.48
RAB9A P51151 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
TNKS O95271 4/20 0.47
CDC25B P30305 2/20 0.45
MAPK14 Q16539 1/20 0.44
GABRP O00591 1/20 0.43
GABRD O14764 1/20 0.43
GABRA1 P14867 1/20 0.43
GABRB1 P18505 1/20 0.43
GABRG2 P18507 1/20 0.43
GABRB3 P28472 1/20 0.43
GABRA5 P31644 1/20 0.43
GABRA3 P34903 1/20 0.43
GABRA2 P47869 1/20 0.43
GABRB2 P47870 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4764744 0.83 KDM4E (0.52) ALDH1A1KDM4ENPC1LMNAHPGD
SCHEMBL31240662 0.74 PRMT5 (0.46) ALDH1A1NPC1MAPK14GABRPGABRD
SCHEMBL22201443 0.73 ALDH1A1 (0.59) ALDH1A1KDM4ENPC1LMNAHPGD
SCHEMBL4775275 0.73 MAPK14 (0.41) ALDH1A1NPC1MAPK14GABRPGABRD
SCHEMBL7596588 0.73 MAPK14 (0.41) LMNAMAPK14GABRPGABRDGABRA1
SCHEMBL17611047 0.73 GABRA5 (0.51) ALDH1A1NPC1MAPK14GABRPGABRD
SCHEMBL828493 0.73 TNKS (0.63) ALDH1A1KDM4ENPC1LMNAHPGD
SCHEMBL29639160 0.73 TNKS (0.63) ALDH1A1KDM4ENPC1LMNAHPGD
Hydrochloric Acid SCHEMBL6648959 0.72 ALDH1A1 (0.61) ALDH1A1KDM4ENPC1LMNAHPGD
SCHEMBL2962988 0.71 GABRA1 (0.48) ALDH1A1KDM4ENPC1LMNARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1020445-B1 FUSED PYRIDINE DERIVATIVES EISAI R&D MAN CO LTD (JP) 2008-08-13 EP disclosed
US-6875761-B2 Certain 1,3-disubstituted isoquinoline derivatives EISAI CO., LTD. (JP) 2005-04-05 US disclosed
US-20040204421-A1 Certain 1,3-disubstituted isoquinoline derivatives EISAI CO., LTD. 2004-10-14 US disclosed
US-6790844-B2 MUSCLE RELAXANTS; ANTISEROTONINE AGENT EISAI CO., LTD (JP) 2004-09-14 US disclosed
US-6340759-B1 ANTISPASMODIC AGENTS EISAI CO., LTD. (JP) 2002-01-22 US disclosed
EP-1020445-A1 FUSED PYRIDINE DERIVATIVES Eisai Co., Ltd. (JP) 2000-07-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040204421-A1 Certain 1,3-disubstituted isoquinoline derivatives MUSK, HTR1A, RYR1 ALDH1A1 1071/4885KDM4E 1058/4885NPC1 4576/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.